Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 18/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP21 | Q9UK80 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987267 | 0.89 | GLS (0.56) | GLSMEN1KMT2A | |
| SCHEMBL15043787 | 0.78 | GLS (0.57) | GLS | |
| SCHEMBL24953526 | 0.70 | SCD (0.50) | MEN1KMT2A | |
| SCHEMBL21484176 | 0.69 | GLS (0.82) | GLS | |
| SCHEMBL24953752 | 0.68 | OGA (0.36) | — | |
| SCHEMBL14987620 | 0.67 | GLS (0.66) | GLS | |
| SCHEMBL14987626 | 0.67 | GLS (1.00) | GLS | |
| SCHEMBL14987636 | 0.66 | GLS (1.00) | GLS | |
| SCHEMBL14987281 | 0.65 | GLS (1.00) | GLSMEN1KMT2A | |
| SCHEMBL14987635 | 0.65 | GLS (1.00) | GLSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885MEN1 2330/4885KMT2A 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.